X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aurobindo Pharma with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ACTAVIS (US) - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   ACTAVIS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
ACTAVIS
Dec-14
AUROBINDO PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs89517,702-   
Low Rs62210,798-   
Sales per share (Unadj.) Rs254.63,187.6-  
Earnings per share (Unadj.) Rs39.3-397.8-  
Cash flow per share (Unadj.) Rs46.6292.5-  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs160.06,913.9-  
Shares outstanding (eoy) m585.88265.90-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.5 66.6%   
Avg P/E ratio x19.3-35.8 -53.9%  
P/CF ratio (eoy) x16.348.7 33.4%  
Price / Book Value ratio x4.72.1 230.1%  
Dividend payout %6.40-   
Avg Mkt Cap Rs m444,3903,789,034 11.7%   
No. of employees `00014.021.6 64.7%   
Total wages/salary Rs m17,6780-   
Avg. sales/employee Rs Th10,667.839,240.4 27.2%   
Avg. wages/employee Rs Th1,264.30-   
Avg. net profit/employee Rs Th1,645.8-4,896.8 -33.6%   
INCOME DATA
Net Sales Rs m149,157847,593 17.6%  
Other income Rs m1,159-2,115 -54.8%   
Total revenues Rs m150,316845,478 17.8%   
Gross profit Rs m34,343108,885 31.5%  
Depreciation Rs m4,276183,535 2.3%   
Interest Rs m66726,735 2.5%   
Profit before tax Rs m30,558-103,500 -29.5%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,592 0.0%   
Tax Rs m7,597-5,321 -142.8%   
Profit after tax Rs m23,012-105,771 -21.8%  
Gross profit margin %23.012.8 179.2%  
Effective tax rate %24.95.1 483.5%   
Net profit margin %15.4-12.5 -123.6%  
BALANCE SHEET DATA
Current assets Rs m92,062446,573 20.6%   
Current liabilities Rs m66,223325,683 20.3%   
Net working cap to sales %17.314.3 121.5%  
Current ratio x1.41.4 101.4%  
Inventory Days Days10658 182.7%  
Debtors Days Days6866 102.1%  
Net fixed assets Rs m62,919103,500 60.8%   
Share capital Rs m5860-   
"Free" reserves Rs m93,1330-   
Net worth Rs m93,7191,838,399 5.1%   
Long term debt Rs m1,814963,357 0.2%   
Total assets Rs m162,4943,369,180 4.8%  
Interest coverage x46.8-2.9 -1,629.9%   
Debt to equity ratio x00.5 3.7%  
Sales to assets ratio x0.90.3 364.9%   
Return on assets %14.6-2.3 -621.2%  
Return on equity %24.6-5.8 -426.8%  
Return on capital %32.7-3.0 -1,087.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m45,6130-   
CASH FLOW
From Operations Rs m32,786145,548 22.5%  
From Investments Rs m-17,870-348,498 5.1%  
From Financial Activity Rs m-19,153195,806 -9.8%  
Net Cashflow Rs m-4,239-7,144 59.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare AUROBINDO PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: SUVEN LIFE  ORCHID PHARMA LTD  J.B.CHEMICALS  DR. REDDYS LAB  VENUS REMEDIES  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS